4

4D Molecular Therapeutics

Develops gene therapies using AAV vectors

Vice President - Clinical Development

Clinical Research OperationsConfirmed live in the last 24 hours
Full-timeRemote in USA$350k - $430k

About the Job

Requirements

  • An MD degree is required.
  • A minimum of 8 years of biopharma industry experience in drug development is required.
  • Experience with Phase 3 ophthalmology development is required.
  • Experience with NDA, BLA, or MAA submissions is required.
  • Demonstrated ability to plan and conduct clinical trials, ensuring high-quality execution and results within established timelines, is required.
  • Experience working effectively in cross-functional teams and workstreams, including pharmacovigilance, biostatistics, clinical operations, and regulatory affairs, is required.
  • An up-to-date understanding of the ophthalmic competitive landscape, with a focus on retina, is required.
  • Ability to understand complex data and translate it into key messages is required.
  • Experience successfully presenting and interacting with the Ophthalmic Retina Community and regulatory authorities in the US, EU, and APAC is required.
  • An integrated understanding of FDA, EMA, ICH, and GCP guidelines is required.
  • A track record of thinking strategically and executing to strategy is required.
  • Demonstrated success influencing colleagues and senior leaders across departments is required.
  • Experience building and leading teams and driving engagement in a matrixed environment is required.
  • A track record of developing talent is required.

Responsibilities

  • Serve as the primary medical monitor for multiple ophthalmology clinical trials, overseeing patient safety, data integrity, and protocol adherence throughout study execution.
  • Direct and mentor a team of medical monitors, maintaining accountability for real-time monitoring activities and timely delivery of clinical trial outputs.
  • Provide medical leadership for cross-functional internal workstreams, including pharmacovigilance, biostatistics, clinical operations, and regulatory affairs.
  • Oversee and lead teams responsible for development plans, study protocols, amendments, ICFs, IBs, INDs, annual reports, CSRs, regulatory response documents, and other regulatory submissions or documents.
  • Collaborate with Clinical Operations and be accountable for clinical trial conduct and timelines for key deliverables.
  • Keep current with compliance and SOPs, and adhere to ICH, GCP, and relevant regulatory guidelines.
  • Provide medical leadership for internal audits and regulatory inspections.
  • Assist in preparing materials for Advisory Board and BOD meetings.
  • Represent the company and lead interactions and collaborations with potential partners.
  • Represent the Ophthalmology Therapeutic Area with external stakeholders, including patients and patient advocacy groups, external experts, investors, and the ophthalmic and biotech business communities.
  • Travel domestically and internationally as required, approximately 20%.

Desired Qualifications

  • Clinical training in Ophthalmology is preferred.
  • Retina fellowship training is a plus.
  • Board certification or equivalent is preferred.
  • Retinal disease experience is highly preferred.
  • Drug approvals are a plus.
  • Experience with gene therapy, other areas of drug development, and commercialization is a plus.
  • Prior clinical trial experience in retina is highly preferred.
  • Prior interactions with FDA and EMA regulatory agencies are desirable.

About the Company

4D Molecular Therapeutics

Develops gene therapies using AAV vectors

4D Molecular Therapeutics develops gene therapies using its Therapeutic Vector Evolution platform to create adeno-associated virus (AAV) delivery vectors that transport therapeutic genes to patients’ cells. This clinical-stage biotech focuses on genetic diseases such as cystic fibrosis, delivering genetic material through engineered AAV vectors in targeted tissues. Its product approach involves R&D and clinical trials to test safety and efficacy, followed by commercialization through direct sales or partnerships with larger pharmaceutical companies. The company differentiates itself with a proprietary vector evolution technology that enables tailored, precise gene delivery and by pursuing funding and collaborations (e.g., with the Cystic Fibrosis Foundation) to advance therapies like 4D-710. The goal is to bring gene therapies to market to treat serious genetic diseases and improve patient outcomes, funded by equity investments, strategic partnerships, and future product sales.

Company size
201-500
Company stage
IPO
Headquarters
Emeryville, CA
Founded
2013

Recently Posted Jobs

Explore more opportunities at 4D Molecular Therapeutics

See more jobs